Dörner et al. Remibrutinib (BTKi) in pSS. + study in pSS! Improved ESSDAI (disease activity), no effect ESSPRI (PRO), trend to improve salivary flow, + effect on multiple labs. @RheumNow #ACR22 Abstr#1113
Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study - ACR Meeting Abstracts
